NCT02393586 is a Phase 1 clinical trial of Faropenem in Tuberculosis, sponsored by National University Hospital, Singapore.

Who is sponsoring NCT02393586?

NCT02393586 is sponsored by National University Hospital, Singapore.

What drugs are being tested in NCT02393586?

Interventions in NCT02393586: Faropenem, Amoxicillin/clavulanic acid 500mg/125mg, Rifampicin.

What condition does NCT02393586 study?

NCT02393586 studies Tuberculosis.

Is NCT02393586 still recruiting?

NCT02393586 is currently completed. Last updated 3 April 2017.

Last reviewed 2017-04-03 · How we verify

NCT02393586

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluating Pharmacokinetics and Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Single Doses of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers

Completed Phase 1 Last updated 3 April 2017

What this trial tests

Phase 1 trial testing Faropenem in Tuberculosis in 43 participants. Completed in 1 October 2015.

Timeline

1 February 2015

Primary endpoint
1 October 2015

1 October 2015

Quick facts

Lead sponsor	National University Hospital, Singapore
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	43
Start date	1 February 2015
Primary completion	1 October 2015
Estimated completion	1 October 2015
Sites	1 location across Singapore

Drugs / interventions tested

Faropenem (FAROPENEM) — full drug profile →
Amoxicillin/clavulanic acid 500mg/125mg — full drug profile →
Rifampicin (Rifampicin) — full drug profile →

Conditions studied

Tuberculosis — all drugs for Tuberculosis →

Sponsor

National University Hospital, Singapore

Who can join

21 and older, any sex, with Tuberculosis. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Cumulative WBA
Time frame: 8 hours
Cumulative bactericidal activity (WBA) reported as change in Mtb log CFU per day based on values observed (AUC)

Sponsor's own description

The purpose of this study is to evaluate the bactericidal activity against Mycobacterium tuberculosis of faropenem boosted with amoxicillin/clavulanic acid. Pharmacokinetics (PK) and Whole blood Bactericidal Activity (WBA) will be measured in healthy volunteers following single doses of faropenem plus amoxicillin/clavulanic acid.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Activity of faropenem with and without rifampicin against Mycobacterium tuberculosis: evaluation in a whole-blood bactericidal activity trial.
Gurumurthy M, Verma R, Naftalin CM, Hee KH, et al · · 2017 · cited 15× · PMID 28333342 · DOI 10.1093/jac/dkx081

Verify or expand the search:

Other trials of Faropenem

Trials testing the same drug.

NCT06804096 — Efficacy and Safety of Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP) · Phase 4 · recruiting
NCT02381470 — Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients Wi · Phase 2 · completed

Other recruiting trials for Tuberculosis

Currently open trials in the same condition.

NCT05917210 — Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda · NA · recruiting
NCT07170735 — Quantitative Measurement of Plasma and Urine MTB Cell-free DNA Level · recruiting
NCT07484490 — Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in Tuberculosis · NA · recruiting
NCT06318416 — Precision Rifampin Trial for Personalized Dosing · Phase 1 · recruiting
NCT07170800 — A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets · Phase 2 · recruiting

Other National University Hospital, Singapore trials

Trials by the same sponsor.

NCT06027983 — Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors · Phase 1, PHASE2 · not yet recruiting
NCT07460505 — Mandibular Advancement to Reduce Ventricular Load and Improve Quality-of-life in Heart Failure · NA · not yet recruiting
NCT07319676 — Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas · Phase 1, PHASE2 · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07091175 — Dupilumab Therapy in Nephrotic Syndrome in Children · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02393586 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National University Hospital, Singapore
Last refreshed: 3 April 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02393586.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing